StkP_446–60-HLA-DRB1*1501-tetramer binding T-cells secrete IFN-gamma.

<p>A tetramer binding T-cell line (unfilled colums) and a separate T-cell clone from HV2 were stimulated with StkP_446–60 peptide (10 micromolar final concentration-vertical lines), recombinant StkP protein (10 ug/ml final concentration-chequered) or media (control-no pattern) for 16 hours. Interferon gamma secreting cells were enumerated by the ELISPot assay.</p

Identifying pneumococcal specific T-cells with a Class 2 tetrameric complex.

<p>Dot plots showing tetramer binding of CD4+T-cells from various cellular sources. Column I shows binding of CD4+ T-cells to the StkP_446–60-HLA-DRB1*1501 tetrameric complexes and column II indicates staining with a control CLIP DRB1*1501 tetramer. StkP_446–60-tetramer and control tetramer binding of a known StkP_446–60-specific IFN –gamma secreting T cell clone from HV1 is shown in A. As StkP_446–60-tetramer staining of <i>ex-vivo</i> samples (B) was not detectable in HV2, anti-PE magnetic beads were used to enrich with consequent detection of StkP_446–60-tetramer binding (C). StkP_446–60-tetramer binding CD4+ T-cells were also identified after 10 days expansion of HV2 PBMC with StkP_446–60 peptide (D). This StkP_446–60-tetramer binding population was sorted by flow cytometry and further expanded <i>in vitro</i> for 2 weeks with a subsequent further enrichment of StkP_446–60-tetramer binding cells (E).</p

Phenotype of Pneumococcal specific T-cells.

<p>The phenotype of tetramer binding T-cells HV1-8, who had detectable tetramer binding was evaluated using concomitant staining of T-cell surface markers. T-cell memory subsets were identified on the basis of CCR7, CD45RA, CD27 and CD28 surface expression, (an example of which is shown in A). The frequencies of central memory (CM), effector memory, naive and mature CD45RA+ CCR7- subsets were determined in the StkP_446–60-tetramer binding and StkP_446–60-tetramer-negative populations in 8 healthy adults (B). CD38 expression was also determined in the StkP_446–60-tetramer binding and the StkP_446–60-tetramer -negative CD4+ T-cells (shown in HV3 in C, grey outline is tetramer positive cells and black outline is tetramer negative CD4+ T-cells). D shows CD38 expression in StkP_446–60-tetramer positive (grey filled column) and negative (unfilled) cells from 8 healthy adults with a significant difference in the mean expression (Wilcoxon signed rank test, p = 0.02).</p

Allele frequencies (AF) of the HLA alleles of the normal population, patients with DHF who did not develop shock and patients who developed shock.

<p>Allele frequencies (AF) of the HLA alleles of the normal population, patients with DHF who did not develop shock and patients who developed shock.</p

Allele frequencies (AF) of the HLA alleles of normal population and patients with primary (PD) and secondary dengue (SD).

<p>Allele frequencies (AF) of the HLA alleles of normal population and patients with primary (PD) and secondary dengue (SD).</p

Allele frequencies (AF) of the HLA types of normal population (who so far have not reported a symptomatic dengue infection) and patients with acute DHF.

<p>Allele frequencies (AF) of the HLA types of normal population (who so far have not reported a symptomatic dengue infection) and patients with acute DHF.</p

Clinical characteristics of DHF patients with primary and secondary dengue.

<p>Clinical characteristics of DHF patients with primary and secondary dengue.</p

Additional file 1: Table S1. of Patterns and causes of liver involvement in acute dengue infection

Number of patients assessed at each time point. (DOCX 11 kb

Additional file 2: Figure S1. of Patterns and causes of liver involvement in acute dengue infection

Standard curves for determining viral loads. A: standard curve for DENV-1. B: standard curve for DEN-2. C: standard curve for DENV-3. D: standard curve for DENV-4. (TIF 497 kb

Additional file 1: of Activated innate lymphoid cell populations accumulate in human tumour tissues

Figure S1. Representative staining of ILC populations. ILC were gated on lineage negative, CD45+, CD127+ cells and based on the expression of CRTH2 and c-Kit divided into ILC1 (CRTH2-, c-Kit-), ILC2 (CRTH2+, c-Kit +/−) and ILC3 (CRTH2-, c-Kit+). Figure S2 Representative example of ILC1, ILC2, ILC3 phenotypic analysis from benign breast tissue. Figure S3 Representative example of ILC1, ILC2, ILC3 phenotypic analysis from malignant breast tissue. Figure S4 Representative example of ILC1, ILC2, ILC3 phenotypic analysis from malignant GI tumour tissue. Figure S5 Representative example of ILC1, ILC2, ILC3 phenotypic analysis from paralesional GI tumour tissue. Table S1 Patient characteristics. (PDF 5287 kb